-+ 0.00%
-+ 0.00%
-+ 0.00%

Mestag Therapeutics appoints Philip Astley-Sparke and Victor Sandor to board

PUBT·10/20/2026 07:49:00
Listen to the news
Mestag Therapeutics appoints Philip Astley-Sparke and Victor Sandor to board
  • Mestag Therapeutics appointed Philip Astley-Sparke and Victor Sandor to its board as it advances its cancer treatment program.
  • The Phase 1 STARLYS trial is enrolling patients with advanced solid tumors to evaluate MST-0312, a bispecific antibody.
  • Astley-Sparke is Replimune’s executive chairman; Sandor previously served as Array BioPharma’s chief medical officer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Forbion Capital Partners Management Services BV published the original content used to generate this news brief on October 20, 2026, and is solely responsible for the information contained therein.